BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $41

Benzinga · 3d ago
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $40 to $41.